Exercise Intervention Among Men With Prostate Cancer Initiating Androgen Deprivation Therapy

Exercise Intervention Among Men With Prostate Cancer Initiating Androgen Deprivation Therapy: A Pilot Study

This research study is evaluating the impact and feasibility of a 12-week brisk walking and moderate strength training exercise intervention including a virtual component in men who are initiating androgen deprivation therapy (ADT) for prostate cancer

Study Overview

• Status: Completed
• Conditions: Prostate Cancer
• Intervention / Treatment: Other: Exercise Intervention

Detailed Description

Androgen deprivation therapy (ADT) is a key treatment of prostate cancer. While this therapy improves prostate cancer outcomes, ADT also has a variety of short- and long-term adverse effects, including increased body weight, loss of lean muscle mass, reductions in quality of life, and increased risk of cardiovascular disease. Studies have shown that among men with prostate cancer, physical activity is associated with improved outcomes, including a reduced risk of mortality, from prostate cancer and other causes. Our hypothesis is that physical activity will improve some of the physical and emotional side effects associated with ADT. Physical activity, such as brisk walking and moderate strength training, offers a lifestyle factor that may improve some of the side effects, and is low-cost and easy to do.

The investigators are conducting this study to evaluate the impact and feasibility of a 12-week moderate-intensity aerobic and strength training exercise intervention, including a virtual component. The intervention includes brisk walking and moderate strength training, and involves home-based exercises, in-person sessions with an oncology-trained exercise physiologist, optional group training sessions, and weekly training goals. Participants will have access to a personalized web-based platform called Postwire, which will include videos of training sessions, and will allow participants to easily communicate with the study staff and with other study participants.

• Study Type: Interventional
• Enrollment (Actual): 13
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Massachusetts
    • Boston, Massachusetts, United States, 02215
      • Dana Farber Cancer Institute

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 80 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Male

Description

Inclusion Criteria:

• Written informed consent prior to any study-related procedures
• History of histologically confirmed prostate cancer
• Initiating or within 30 days of initiating ADT
• ECOG performance status of 0 or 1
• At least 18 years old and no older than 80 years
• Physically able to exercise and have physician consent from their treating physician to start a physical activity program
• English speaking and able to read English
• Have access to and are able to use the internet at a minimum of once per week
• Sufficient proficiency and confidence to use the internet and follow video-based instructions, as determined by the eligibility questionnaire to be completed by the participant
• Willingness to be randomized

Exclusion Criteria:

• Self-reported inability to walk 2 blocks (at any pace)
• Currently physically active (> 90 minutes of moderate or vigorous physical activity per week) as determined by Leisure Score Index of Godin Leisure-Time Exercise Questionnaire [LSI])
• Previously on ADT
• Radiologic evidence of distant disease
• Cardiovascular, respiratory or musculoskeletal disease or joint problems that preclude moderate physical activity. Examples would include unstable angina, recent myocardial infarction, oxygen-dependent pulmonary disease, and osteoarthritis requiring imminent joint replacement. Moderate arthritis that does not preclude physical activity is not a reason for ineligibility.
• Psychiatric disorders or conditions that would preclude participation in the study intervention (e.g., untreated major depression or psychosis, substance abuse, severe personality disorder)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: SUPPORTIVE_CARE
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: NONE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Exercise Intervention; 12-weeks brisk walking and strength training; 150 minute moderate aerobic activities, such as brisk walking; Strength training 3 days /week; One on one sessions with exercise physiologist; Optional group sessions	Other: Exercise Intervention; 12-week moderate-intensity aerobic and strength training exercise intervention
NO_INTERVENTION: Usual Care; Usual Care provided

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change from Baseline in Physical Performance at 12 weeks	The 6 Minute Walk Test will be performed at the clinic, where the participants will wear tennis shoes and will walk indoors on a flat surface for 6 minutes.	Baseline and 12 weeks
Change from Baseline in Physiologic Measurements at 12 weeks	Measuring heart rate and resting pulse by counting the number of beats per minute at the wrist of each participant.	Baseline and 12 weeks
Change from Baseline in Blood Pressure at 12 weeks	The investigators will obtain participant's blood pressure from the most recent clinical visit.	Baseline and 12 weeks
Change from Baseline in Body Composition at 12 weeks	Obtain body composition (total fat and lean body mass) by conducting dual energy X-ray absorptiometry (DEXA) scans.	Baseline and 12 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Fatigue	The Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-F) is a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function.	Baseline and 12 weeks
Physical Functioning	The investigators will assess changes in physical functioning from study enrollment to the completion of the study period using the European Organization for the Research and Treatment of Cancer (EORTC) QLQ-C30 (version 3) and the Prostate Cancer Specific EORTC questionnaire.	Baseline and 12 weeks
Minutes of Physical Activity	The investigators will assess changes in activity from baseline to 12-weeks using the 7-Day Physical Activity Recall (PAR)	Baseline and 12 weeks
Anthropometric Measures	The investigators will assess changes in height from baseline to 12 weeks using a tape measure.	Baseline and 12 weeks
Anthropometric Measures	The investigators will assess changes in weight from baseline to 12 weeks using a scale.	Baseline and 12 weeks
Anthropometric Measures	The investigators will assess changes in waist circumference from baseline to 12 weeks using a tape measure.	Baseline and 12 weeks.
Biomarkers	The investigators will assess PSA at baseline and 12-weeks in both the usual care and intervention arm.	Baseline and 12 weeks.
Biomarkers	The investigators will assess testosterone levels at baseline and 12-weeks in both the usual care and intervention arm.	Baseline and 12 weeks.
Measure adherence	The investigators will evaluate adherence rates to study procedures by using self-report and FitBit	Baseline and 12 weeks
Measure feasibility	Feasibility measured by number of eligible members of the targeted population	Baseline and 12 weeks
Measure feasibility	Feasibility measured by recruitment rates	Baseline and 12 weeks
Measure feasibility	Feasibility measured by refusal rates for participation and randomization	Baseline and 12 weeks
Measure feasibility	Feasibility measured by level of engagement with Postwire and with other study participants.	Baseline and 12 weeks

Collaborators and Investigators

• Sponsor: Dana-Farber Cancer Institute

Study record dates

Study Major Dates

• Study Start (ACTUAL): December 8, 2017
• Primary Completion (ACTUAL): December 12, 2019
• Study Completion (ACTUAL): December 12, 2019

Study Registration Dates

• First Submitted: February 6, 2017
• First Submitted That Met QC Criteria: February 28, 2017
• First Posted (ACTUAL): March 3, 2017

Study Record Updates

• Last Update Posted (ACTUAL): September 22, 2021
• Last Update Submitted That Met QC Criteria: September 21, 2021
• Last Verified: September 1, 2021

More Information

Terms related to this study

• Keywords: Prostate Cancer
• Additional Relevant MeSH Terms: Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Genital Neoplasms, Male; Prostatic Diseases; Prostatic Neoplasms
• Other Study ID Numbers: 16-515

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No